Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, CA, with a bold mission to eradicate cancer by targeting one of its most commonly mutated signaling pathways, the RAS MAPK pathway. With a promising pipeline of therapeutic programs, Erasca aims to make a transformative difference in the lives of millions affected by a wide range of devastating cancers, offering hope for a brighter and cancer-free future.
Founded in 2018 by Jonathan E. Lim, M.D., Erasca is driven by a dynamic culture and a commitment to serious cancer-fighting science. The company's modality-agnostic approach and comprehensive focus on the RAS MAPK pathway position it as a leader in precision oncology, with the potential to bring about significant advancements in cancer treatment and improve the lives of patients worldwide.
Generated from the website